---
title: "INT'L GROUP plans to participate in the auction for 100% equity of Huatuo Pharmaceutical to enhance market share"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/241998596.md"
description: "INT'L GROUP announced that its wholly-owned subsidiary, Zhejiang INT'L Pharmaceutical Co., Ltd., intends to participate in the auction for 100% equity of Huadong Pharmaceutical through the Zhejiang Property Exchange, with a listing reserve price of 369 million yuan. This move aims to enhance the company's market share and industry concentration in Zhejiang Province, strengthen its bargaining power with upstream suppliers, and promote the company's high-quality development"
datetime: "2025-05-27T11:15:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/241998596.md)
  - [en](https://longbridge.com/en/news/241998596.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/241998596.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/241998596.md) | [English](https://longbridge.com/en/news/241998596.md)


# INT'L GROUP plans to participate in the auction for 100% equity of Huatuo Pharmaceutical to enhance market share

According to the announcement from INT'L GROUP (000411.SZ), in order to further deepen the company's business layout in Zhejiang Province and enhance market share and industry concentration, the wholly-owned subsidiary Zhejiang INT'L Pharmaceutical Co., Ltd. ("INT'L Pharmaceutical") plans to participate in the auction for 100% equity of Zhejiang Huadong Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Huadong Pharmaceutical" or "transaction target") through the designated platform of Zhejiang Property Exchange, with a listing base price of 369 million yuan. The actual transfer price will be based on the final auction transfer price from Zhejiang Property Exchange.

The wholesale business of the transaction target Huadong Pharmaceutical has significant advantages in the grassroots public medical market, while its retail segment, Huadong Chain, is among the top 100 pharmaceutical retail enterprises, forming a high synergy with INT'L GROUP's existing business.

This transaction aligns with the company's strategic planning and business development needs, helping to enhance the company's market share in pharmaceutical wholesale and retail in the Zhejiang market, strengthen bargaining power with upstream suppliers, and increase influence over end consumers, thereby promoting the company's high-quality development

### 相關股票

- [INT'L GROUP (000411.CN)](https://longbridge.com/zh-HK/quote/000411.CN.md)

## 相關資訊與研究

- [Air India to operate special flights for UAE on March 8 amid Gulf crisis](https://longbridge.com/zh-HK/news/278239013.md)
- [Trump: They have agreed to quadruple production of "exquisite class" weaponry](https://longbridge.com/zh-HK/news/278164233.md)
- [Pizu Group Details Tajikistan Mining Loan Deal and Planned 45% Stake in Kanzi Diyor](https://longbridge.com/zh-HK/news/278384508.md)
- [CATL and Rio Tinto target electrification of mining operations](https://longbridge.com/zh-HK/news/278348983.md)
- [Xiaomi bought back 3 million class B shares for HK$100 million on Mar 10, HKEX filing shows](https://longbridge.com/zh-HK/news/278546704.md)